CN1351597A - 抗糖尿病的新型多晶形物、其制备方法和含有它们的药物组合物 - Google Patents

抗糖尿病的新型多晶形物、其制备方法和含有它们的药物组合物 Download PDF

Info

Publication number
CN1351597A
CN1351597A CN00807705A CN00807705A CN1351597A CN 1351597 A CN1351597 A CN 1351597A CN 00807705 A CN00807705 A CN 00807705A CN 00807705 A CN00807705 A CN 00807705A CN 1351597 A CN1351597 A CN 1351597A
Authority
CN
China
Prior art keywords
polymorph
ethoxy
phenoxazine
phenyl
oxyethyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00807705A
Other languages
English (en)
Chinese (zh)
Inventor
O·R·戈达姆
R·K·波特拉帕里
R·西里西拉
V·克里斯纳默斯
S·R·达哈玛拉贾
R·S·玛米拉帕里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Research Foundation
Original Assignee
Dr Reddys Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1999/000681 external-priority patent/WO2000063191A1/en
Application filed by Dr Reddys Research Foundation filed Critical Dr Reddys Research Foundation
Publication of CN1351597A publication Critical patent/CN1351597A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN00807705A 1999-04-16 2000-04-17 抗糖尿病的新型多晶形物、其制备方法和含有它们的药物组合物 Pending CN1351597A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/IB1999/000681 WO2000063191A1 (en) 1999-04-16 1999-04-16 Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
WOPCT/IB99/00681 1999-04-16
IN436/MAS/99 1999-04-19
IN436MA1999 1999-04-19

Publications (1)

Publication Number Publication Date
CN1351597A true CN1351597A (zh) 2002-05-29

Family

ID=26318745

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00807705A Pending CN1351597A (zh) 1999-04-16 2000-04-17 抗糖尿病的新型多晶形物、其制备方法和含有它们的药物组合物

Country Status (17)

Country Link
EP (1) EP1171430A1 (pt)
CN (1) CN1351597A (pt)
AU (1) AU3831300A (pt)
BG (1) BG106022A (pt)
BR (1) BR0010683A (pt)
CA (1) CA2370401A1 (pt)
CZ (1) CZ20013711A3 (pt)
EE (1) EE200100529A (pt)
HR (1) HRP20010748A2 (pt)
HU (1) HUP0200758A3 (pt)
IL (1) IL145958A0 (pt)
MX (1) MXPA01010472A (pt)
NO (1) NO20015016L (pt)
PL (1) PL351492A1 (pt)
RU (1) RU2001130883A (pt)
TR (1) TR200103851T2 (pt)
WO (1) WO2000063192A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1263458B1 (en) 2000-03-08 2005-11-16 Novo Nordisk A/S Lowering serum cholesterol
US6897199B2 (en) * 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
JP4563675B2 (ja) 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 置換ピペリジン類、およびヒスタミンｈ３受容体関連疾患の治療のためのその使用
JP2005518391A (ja) 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Ｇｋ活性化剤としてのアミド誘導体
AU2002255017B2 (en) * 2002-04-19 2008-11-13 Faes Farma, S.A. Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic acid
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
EP1625112B1 (en) 2003-05-14 2009-07-22 High Point Pharmaceuticals, LLC Novel compounds for treatment of obesity
AU2004275928B2 (en) 2003-09-30 2010-03-11 Novo Nordisk A/S Melanocortin receptor agonists
EP2298337B1 (en) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
CA2551324C (en) 2004-01-06 2012-11-27 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
WO2005105785A2 (en) 2004-05-04 2005-11-10 Novo Nordisk A/S Indole derivatives for treatment of obesity
US8410047B2 (en) 2004-06-11 2013-04-02 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
ES2391776T3 (es) 2004-11-22 2012-11-29 Novo Nordisk A/S Formulaciones solubles, estables conteniendo insulina con una sal de protamina
KR101066882B1 (ko) 2004-12-03 2011-09-26 트랜스테크 파르마, 인크. 헤테로방향족 글루코키나제 활성화제
ATE536344T1 (de) 2005-07-04 2011-12-15 High Point Pharmaceuticals Llc Histamine h3 receptor antagonisten
AU2006268589B2 (en) 2005-07-14 2011-09-29 Vtv Therapeutics Llc Urea glucokinase activators
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
PL1951658T3 (pl) 2005-11-17 2013-02-28 Lilly Co Eli Antagoniści receptora glukagonu, preparatyka i zastosowania terapeutyczne
ES2388681T3 (es) 2006-03-28 2012-10-17 High Point Pharmaceuticals, Llc Benzotiazoles con actividad de los receptores de histamina H3
PL2079732T3 (pl) 2006-05-29 2012-05-31 High Point Pharmaceuticals Llc 3-(1,3-benzodioksol-5-ylo)-6-(4-cyklopropylopiperazyn-1-ylo)-pirydazyna, jej sole i solwaty oraz jej zastosowanie jako antagonisty receptora histaminowego h3
EP2086951B1 (en) 2006-11-15 2011-12-21 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
WO2008059026A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
EP2099777B1 (en) 2007-01-11 2015-08-12 Novo Nordisk A/S Urea glucokinase activators
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
US20130012432A1 (en) 2010-02-26 2013-01-10 Novo Nordisk A/S Peptides for Treatment of Obesity
CA2792663A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
AU2012234276A1 (en) 2011-03-28 2013-08-29 Novo Nordisk A/S Novel glucagon analogues
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
RS59124B1 (sr) 2013-04-18 2019-09-30 Novo Nordisk As Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
CN111032680A (zh) 2017-03-15 2020-04-17 诺和诺德股份有限公司 能够与黑皮质素4受体结合的双环化合物
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
IN182496B (pt) * 1996-02-20 1999-04-17 Reddy Research Foundation
WO1997027191A1 (en) * 1996-06-19 1997-07-31 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2746099B1 (fr) * 1996-03-13 1998-04-30 Procede ameliore pour la preparation de derives de l'acide 3-(10-phenothiazyl)-propanoique ou 3-(10-phenoxazyl)-propanoique
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
EP1051403A1 (en) * 1998-01-29 2000-11-15 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
NZ504106A (en) * 1998-05-27 2003-02-28 Dr Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
BG106022A (bg) 2002-04-30
IL145958A0 (en) 2002-07-25
PL351492A1 (en) 2003-04-22
NO20015016L (no) 2001-12-11
EE200100529A (et) 2002-12-16
HUP0200758A3 (en) 2003-07-28
RU2001130883A (ru) 2004-03-20
CA2370401A1 (en) 2000-10-26
CZ20013711A3 (cs) 2002-07-17
NO20015016D0 (no) 2001-10-15
TR200103851T2 (tr) 2002-04-22
AU3831300A (en) 2000-11-02
HRP20010748A2 (en) 2003-02-28
EP1171430A1 (en) 2002-01-16
MXPA01010472A (es) 2002-05-06
BR0010683A (pt) 2003-07-01
HUP0200758A2 (hu) 2002-07-29
WO2000063192A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
CN1351597A (zh) 抗糖尿病的新型多晶形物、其制备方法和含有它们的药物组合物
CN100344616C (zh) 用于治疗代谢失调的化合物
CN1190434C (zh) 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
CN1046722C (zh) 杂环化合物及其制备和应用
CN1280574A (zh) 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
CN1750758A (zh) 用于治疗代谢紊乱的化合物
CN1221417A (zh) 具有抗糖尿病、降低血脂、抗高血压性能的噻唑烷二酮化合物,其制备方法及其药物组合物
CN1489463A (zh) 阿托伐他汀半钙的新晶型及其制备方法,以及其它晶型的新制备方法
CN1311767A (zh) 治疗代谢性疾病的糖皮质激素和甲状腺激素受体的配体
CN88101642A (zh) 哌嗪基-杂环化合物
CN1266129C (zh) 具有降血脂和降低血中胆固醇活性的新化合物、其制备方法和含有它们的药物组合物
CN1774244A (zh) 用于治疗代谢紊乱的化合物
CN86106428A (zh) 抗肿瘤方法及其化合物
CN1280575A (zh) 新型三环化合物和其作为药物的用途;其制备方法和包含该化合物的药物组合物
CN1355790A (zh) 采用二氢异吲哚衍生物抑制淀粉样蛋白聚集和使淀粉样蛋白沉积成像的方法
CN1780614A (zh) 用于治疗代谢紊乱的化合物
CN1358175A (zh) 嘧啶酮化合物
CN1026234C (zh) 用于降血糖的噻唑烷二酮衍生物的制备方法
CN1777576A (zh) 用于治疗代谢紊乱的化合物
CN1968687A (zh) 预防和治疗代谢性骨病的含有α－芳基甲氧基丙烯酸酯衍生物的药物组合物
CN87102891A (zh) 硫化内酰胺-n-乙酸衍生物的生产及使用
CN101039921A (zh) 3－[5－氯－4－[(2,4－二氟苄基)氧基]－6－氧代嘧啶－1(6h)－基]－n－(2－羟乙基)－4－甲基苯甲酰胺的晶形
CN1728992A (zh) 具有降低血清葡萄糖和降低血清脂质活性的α－苯硫基羧酸和α－苯氧基羧酸的用途
CN1205704A (zh) 2,7－取代的八氢－吡咯并[1,2－a]吡嗪衍生物
CN1257893C (zh) 具有优异降糖降酯活性的芳烷基氨基酸类ppar全激活剂

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
ASS Succession or assignment of patent right

Owner name: REDDY LAB CO LTD

Free format text: FORMER OWNER: DR. LEI DI RESEARCH FOUNDATION

Effective date: 20020524

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20020524

Address after: Hyderabad

Applicant after: Dr. Reddy's Research Foundation

Address before: Andhra Pradesh

Applicant before: Dr. Reddy's research Foundation

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication